FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:1395 May 8, 1997 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

Edited by D. John Betteridge. 302 pp. St. Louis, Mosby, 1996. $75. ISBN 1-85317-231-6.

Physicians used to have mixed feelings about the treatment of hyperlipidemia. They knew that high lipid concentrations cause heart disease, but they also knew that the lifestyle changes required to correct hyperlipidemia could be difficult to implement and that the available drugs were of doubtful safety and effectiveness, poorly tolerated, or both.

The arrival of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins, has changed all that. Statins lower cholesterol concentrations, the risk of cardiovascular disease, and total mortality rates; they are easy to take; and up until now they have been remarkably free from side effects. However, putting a . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.